Targeting siRNA Missiles to Her2+ Breast Cancer

摘要

The most significant findings here are that HerPBK10 protects siRNA from serum nuclease-mediated degradation, T7 transcribed siRNA is more cytotoxic than synthetic siRNA when delivered to HER2+ breast cancer cells by HerPBK10 in vitro, HerPBK10 directs siRNA-mediated cytotoxicity to HER2+ but not HER2- cells in vitro, the HerPBK10 carrier preferentially accumulates in HER2+ tumors in vivo when delivered systemically (intravenously), and cytotoxicity is associated with siRNA-mediated induction of IFN-alpha.